経肺ドラッグデリバリー市場レポート：2030年までの動向、予測、競合分析

経肺ドラッグデリバリーの動向と予測

世界の経肺ドラッグデリバリー市場は、2024年から2030年までのCAGRが2.5%で、2030年までに推定681億米ドルに達すると予想されます。この市場の主な促進要因は、呼吸器疾患の有病率の上昇、経肺ドラッグデリバリーの利点に対する意識の高まり、在宅医療サービスの需要増です。世界の経肺ドラッグデリバリー市場の将来は、病院・診療所市場や在宅医療市場にビジネスチャンスがあり、有望視されています。

経肺ドラッグデリバリー市場の洞察

Lucintelは、呼吸器疾患の有病率の増加と慢性閉塞性肺疾患の治療に対する有利な償還政策により、慢性閉塞性肺疾患（COPD）が予測期間中最大のセグメントであり続けると予測しています。

この市場の中では、病院薬局の数が世界中で増加しているため、病院・診療所が引き続き大きなセグメントとなるでしょう。

北米は、最新の経肺ドラッグデリバリーデバイスや治療法を患者に提供する先進ヘルスケアシステムにより、引き続き最大の地域となるでしょう。

本レポートでは、以下の11の主要な質問に回答しています：

• Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
• Q.2.どの分野がより速いペースで成長するのか、またその理由は？
• Q.3.今後成長が加速すると思われる地域とその理由は？
• Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
• Q.5.この市場におけるビジネスリスクと競合の脅威は？
• Q.6.この市場における新たな動向とその理由は？
• Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
• Q.8.この市場における新たな開発と、その開発をリードしている企業は？
• Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
• Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
• Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の経肺ドラッグデリバリー市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の経肺ドラッグデリバリー市場の動向（2018-2023）と予測（2024-2030）
• 用途別の世界の経肺ドラッグデリバリー市場
  • 喘息
  • 慢性閉塞性肺疾患
  • アレルギー性鼻炎
  • 嚢胞性線維症
  • その他
• 最終用途別の世界の経肺ドラッグデリバリー市場
  • 病院とクリニック
  • 在宅ケア
• 流通チャネル別の世界の経肺ドラッグデリバリー市場
  • 病院薬局
  • 小売薬局
  • eコマース

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の経肺ドラッグデリバリー市場
• 北米の経肺ドラッグデリバリー市場
• 欧州の経肺ドラッグデリバリー市場
• アジア太平洋の経肺ドラッグデリバリー市場
• その他地域経肺ドラッグデリバリー市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 用途別の世界の経肺ドラッグデリバリー市場の成長機会
  • 最終用途別の世界の経肺ドラッグデリバリー市場の成長機会
  • 流通チャネル別の世界の経肺ドラッグデリバリー市場の成長機会
  • 地域別の世界の経肺ドラッグデリバリー市場の成長機会
• 世界の経肺ドラッグデリバリー市場における新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の経肺ドラッグデリバリー市場の能力拡大
  • 世界の経肺ドラッグデリバリー市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• GlaxoSmithKline
• 3M Company
• Koninklijke Philips
• AstraZeneca
• Boehringer Ingelheim

Pulmonary Drug Delivery Trends and Forecast

The future of the global pulmonary drug delivery market looks promising with opportunities in the hospitals & clinic and home care markets. The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2030 with a CAGR of 2.5% from 2024 to 2030. The major drivers for this market are rising prevalence of respiratory diseases, growing awareness towards the benefits of pulmonary drug delivery, and increasing demand for home-based healthcare services.

A more than 150-page report is developed to help in your business decisions.

Pulmonary Drug Delivery by Segment

The study includes a forecast for the global pulmonary drug delivery by application, end use, distribution channel, and region.

Pulmonary Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Asthma
• Chronic Obstructive Pulmonary Disease
• Allergic Rhinitis
• Cystic Fibrosis
• Others

Pulmonary Drug Delivery Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals & Clinics
• Home Care

Pulmonary Drug Delivery Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Pulmonary Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Pulmonary Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pulmonary drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pulmonary drug delivery companies profiled in this report include-

• Glaxosmithkline
• 3M Company
• Koninklijke Philips
• Astrazeneca
• Boehringer Ingelheim

Pulmonary Drug Delivery Market Insights

Lucintel forecasts that chronic obstructive pulmonary disease (COPD) will remain the largest segment over the forecast period due to increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

Within this market, hospitals & clinics will remain the larger segment due to growing number of hospital pharmacies across the globe.

North America will remain the largest region due to advanced healthcare system, which provides patients with access to the latest pulmonary drug delivery devices and treatments.

Features of the Global Pulmonary Drug Delivery Market

Market Size Estimates: Pulmonary drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pulmonary drug delivery market size by application, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: Pulmonary drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different applications, end uses, distribution channels, and regions for the pulmonary drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pulmonary drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the pulmonary drug delivery market size?

Answer: The global pulmonary drug delivery market is expected to reach an estimated $68.1 billion by 2030.

Q.2 What is the growth forecast for pulmonary drug delivery market?

Answer: The global pulmonary drug delivery market is expected to grow with a CAGR of 2.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the pulmonary drug delivery market?

Answer: The major drivers for this market are rising prevalence of respiratory diseases, growing awareness towards the benefits of pulmonary drug delivery, and increasing demand for home-based healthcare services.

Q4. What are the major segments for pulmonary drug delivery market?

Answer: The future of the pulmonary drug delivery market looks promising with opportunities in the hospitals & clinic and home care markets.

Q5. Who are the key pulmonary drug delivery market companies?

Answer: Some of the key pulmonary drug delivery companies are as follows:

• Glaxosmithkline
• 3M Company
• Koninklijke Philips
• Astrazeneca
• Boehringer Ingelheim

Q6. Which pulmonary drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that chronic obstructive pulmonary disease (COPD) will remain the largest segment over the forecast period due to increasing prevalence of respiratory diseases and favorable reimbursement policies towards the treatment of chronic obstructive pulmonary disease.

Q7. In pulmonary drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region due to advanced healthcare system, which provides patients with access to the latest pulmonary drug delivery devices and treatments.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the pulmonary drug delivery market by application (asthma, chronic obstructive pulmonary disease, allergic rhinitis, cystic fibrosis, and others), end use (hospitals & clinics and home care), distribution channel (hospital pharmacies, retail pharmacies, and e-commerce), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Pulmonary Drug Delivery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Pulmonary Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Pulmonary Drug Delivery Market by Application
  • 3.3.1: Asthma
  • 3.3.2: Chronic Obstructive Pulmonary Disease
  • 3.3.3: Allergic Rhinitis
  • 3.3.4: Cystic Fibrosis
  • 3.3.5: Others
• 3.4: Global Pulmonary Drug Delivery Market by End Use
  • 3.4.1: Hospitals & Clinics
  • 3.4.2: Home Care
• 3.5: Global Pulmonary Drug Delivery Market by Distribution Channel
  • 3.5.1: Hospital Pharmacies
  • 3.5.2: Retail Pharmacies
  • 3.5.3: E-commerce

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Pulmonary Drug Delivery Market by Region
• 4.2: North American Pulmonary Drug Delivery Market
  • 4.2.2: North American Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
• 4.3: European Pulmonary Drug Delivery Market
  • 4.3.1: European Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
  • 4.3.2: European Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
• 4.4: APAC Pulmonary Drug Delivery Market
  • 4.4.1: APAC Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
  • 4.4.2: APAC Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care
• 4.5: ROW Pulmonary Drug Delivery Market
  • 4.5.1: ROW Pulmonary Drug Delivery Market by Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, and Others
  • 4.5.2: ROW Pulmonary Drug Delivery Market by End Use: Hospitals & Clinics and Home Care

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Application
  • 6.1.2: Growth Opportunities for the Global Pulmonary Drug Delivery Market by End Use
  • 6.1.3: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Distribution Channel
  • 6.1.4: Growth Opportunities for the Global Pulmonary Drug Delivery Market by Region
• 6.2: Emerging Trends in the Global Pulmonary Drug Delivery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Pulmonary Drug Delivery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pulmonary Drug Delivery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: 3M Company
• 7.3: Koninklijke Philips
• 7.4: AstraZeneca
• 7.5: Boehringer Ingelheim